What the trial was testing
The MG0002 enrolled 43 patients with myasthenia gravis. The study was sponsored by UCB Pharma and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a mid-stage trial — researchers are testing whether the treatment actually works for the condition. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Meaningful improvement in patients' ability to carry out daily activities — a result that helped support the drug's eventual FDA approval.
Neurology · 2021 · NCT03052751
These findings — that on the daily-activities endpoint (MG-ADL), showing meaningful improvement in swallowing, breathing, and daily function — were published in the Neurology and represent the headline result of the study.
Researchers tracked outcomes across 43 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with myasthenia gravis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rozanolixizumab (Rystiggo) received FDA approval in 2023 for generalized myasthenia gravis in adults who are AChR or MuSK antibody positive. Ask your neurologist whether you qualify and whether Rystiggo or a similar FcRn inhibitor is appropriate for your situation.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open myasthenia gravis trials
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.